Skip to main content
Premium Trial:

Request an Annual Quote

Genome BC to Fund Proof-of-Concept Genomics Projects

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genome British Columbia aims to support efforts to develop genomics technologies and products toward commercialization through a Proof-of-Concept program with partners in the Canadian government.

Funded with nearly C$2.2 million ($2.3 million) each from Genome BC and Western Economic Diversification Canada, the program is aimed at helping to develop POC projects based at academic institutions, Genome BC said in a request for applications.

Genome BC wants the POC program to fund commercialization projects for new genomics-related scientific or technological innovation, to facilitate the advancement of genomics-based discoveries "in a real world setting," and to develop new and novel products and services to where they are ready for licensing, industry investment, or spin out.

The program, which will run through 2015, will support projects of between $50,000 and $250,000 for up to two years. The funding may be staged and dependent on the completion of approved milestones and deliverables.

Genome BC also is strongly encouraging applicants for the POC program to partner with existing facilities in BC, including S&T Innovation Centres, as the program will not provide funding for the building of new infrastructure.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.